Tagged Articles

suvorexant 3 articles

Belsomra sleeping pill linked to suicides

Cases of completed suicides and attempted suicides with the insomnia drug Belsomra have raised concerns with the Institute for Safe Medication Practices (ISMP) in its QuarterWatch review. The organization monitors Food and Drug Administration (FDA) MedWatch adverse event reports each quarter. Belsomra was approved by the FDA in 2014. It contains the active ingredient suvorexant, which works by blocking two newly discovered neurotransmitters called orexins. Neurons that emit orexin send wakefulness signals to the complex neural circuits that regulate sleep and waking cycles. Belsomra was developed under the idea that blocking these wakeful signals at night would help people sleep. During ... Read More

FDA rejects experimental sleeping pill for people with insomnia

A first drug in a new class of insomnia treatments was rejected by the Food and Drug Administration (FDA) because the agency said safety data didn’t support approval of the treatment at the dosing proposed. The drug, called suvorexant, made by Merck & Co., was under review by the FDA in both 30- and 40-milligram doses. The FDA advised Merck that suvorexant was effective at doses as low as 10 milligrams up to 40 milligrams, with 10 milligrams seen as the starting point. As a result, the FDA advised that Merck seek approval for the lowest dosage before it grants ... Read More

Experimental sleep aid helped test patients fall asleep faster, stay asleep longer

An experimental new drug to help insomniacs fall asleep faster and stay asleep longer is showing good results in clinical trials. Suvorexant, made by Merck, is a new type of sleep aid that works differently from others currently on the market. Suvorexant works by targeting and blocking chemical messengers known as orexins that are designed to keep you awake and alert. They originate in the hypothalamus, a major sleep center in the brain. The new drug was tested during a three-month period in two separate trials of more than 1,000 people who suffer from insomnia. Patients in the first trial ... Read More